TRAX (First Tracks Biotherapeutics) Stock Based Compensation: $26.83 Mil (TTM As of Dec. 2024)


TRAX First Tracks Biotherapeutics Inc TRAX
12 GF Score
Price $36.24
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics Stock Based Compensation?

First Tracks Biotherapeutics TRAX +11.85% 12 Stock Based Compensation is $26.83 Mil as of Dec. 2024. GuruFocus rates TRAX with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

First Tracks Biotherapeutics's Stock Based Compensation for the six months ended in Dec. 2024 was $26.83 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was $26.83 Mil.

First Tracks Biotherapeutics Stock Based Compensation Related Terms

First Tracks Biotherapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics Stock Based Compensation Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
Stock Based Compensation
18.39 26.83

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
Stock Based Compensation 18.39 26.83
TRAX
12GF Score
First Tracks Biotherapeutics Inc TRAX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2024 was $26.83 Mil.

What does a Stock Based Compensation of $26.83 Mil mean?
First Tracks Biotherapeutics (TRAX) has a Stock Based Compensation of $26.83 Mil as of Dec. 2024. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for First Tracks Biotherapeutics and its competitors.
Is First Tracks Biotherapeutics' Stock Based Compensation too high?
First Tracks Biotherapeutics' current Stock Based Compensation is $26.83 Mil. Overall, First Tracks Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' Stock Based Compensation compare to ALT and RGNX?
First Tracks Biotherapeutics' Stock Based Compensation of $26.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for First Tracks Biotherapeutics and its competitors. First Tracks Biotherapeutics's current Stock Based Compensation is $26.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (TRAX) has a current Stock Based Compensation of $26.83 Mil. The current Stock Based Compensation is $26.83 Mil. First Tracks Biotherapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For First Tracks Biotherapeutics (TRAX), the current Stock Based Compensation is $26.83 Mil as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges B43:Germany
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
12GF Score

Get the complete analysis for TRAX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$36.24
Price